Alucent Biomedical adds to scientific advisory board, expands portfolio with AF fistula application


Alucent Biomedical has announced Stanford vascular surgeon Venita Chandra (Stanford University Medical Center, Stanford, USA) will join the company’s scientific advisory board. The news comes as Alucent seeks to expand its clinical trial portfolio beyond the treatment of peripheral arterial disease (PAD) of the lower extremities and adapt its Natural Vascular Scaffolding (Alucent NVS) for the maturation and preservation of arteriovenous fistula (AVF) for haemodialysis.

As end-stage renal disease continues to rise, there is a growing need for haemodialysis. AVFs are recommended as the preferred type of vascular access for haemodialysis, as they have superior patency rates, fewer complications, and lower health care costs. Early pre-clinical studies where Alucent NVS therapy was applied at fistula creation resulted in facilitated maturation and the promotion of outward remodelling of the AVF.

Chandra is board certified in both general and vascular surgery. She is a clinical associate professor of surgery in the Division of Vascular Surgery at Stanford University Medical Center. She also serves as the co-medical director of the Stanford Advanced Wound Care Center and the program director of the Vascular Surgery Fellowship and Vascular Surgery Residency Programs at the Stanford University School of Medicine.


Please enter your comment!
Please enter your name here